Shared insight on the clinical impact circulating tumor DNA testing has had on the management of patients with breast cancer.
EP. 1: An Overview of Minimal Residual Disease (MRD) Testing
Expert oncologist Aditya Bardia, MD, MPH, provides a broad overview of minimal residual disease testing across a number of tumor types and clinical settings.
EP. 2: Applications of ctDNA Assessment in Early Breast Cancer
Barry Rosen, MD, provides an overview of circulating tumor DNA’s role in early stage breast cancer detection and management.
EP. 3: Applications of ctDNA Assessment in Metastatic Breast Cancer and Relapse
Aditya Bardia, MD, MPH, shares insight on how circulating tumor DNA is used in metastatic breast cancer and relapse detection.
EP. 4: Role of ctDNA in the Neoadjuvant Setting of Breast Cancer
Expert perspectives on the value of circulating tumor DNA in the neoadjuvant setting of breast cancer management.
EP. 5: Role of ctDNA in the Adjuvant Setting of Breast Cancer
Aditya Bardia, MD, MPH, and Barry Rosen, MD, discuss the role of circulating tumor DNA in the adjuvant setting of breast cancer.
EP. 6: ctDNA in Breast Cancer: Cancer Detection Vs Therapy Selection
A brief synopsis on the use of circulating tumor DNA for cancer detection versus treatment selection in breast cancer management.
EP. 7: Other Clinical Studies on ctDNA Use in Breast Cancer
Shared insight on how clinical trial data behind circulating tumor DNA in breast cancer may affect future treatment strategies.
EP. 8: Practical Advice on the Use of ctDNA Testing in Breast Cancer
Closing out their discussion on circulating tumor DNA in breast cancer management, experts share closing advice on practical strategies to use testing in clinic.
Sotigalimab/Pembrolizumab Combo Continues to Show Clinical Activity in Frontline Melanoma
Dr. Halmos on Trastuzumab Deruxtecan in NSCLC
Dr. Kris on Immunotherapy in NSCLC Without Driver Mutations
Checkpoint Inhibitor Challenges Warrant Consideration for a Targeted Approach in NSCLC
2 Clarke DriveSuite 100Cranbury, NJ 08512
© 2022 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.